Antibiotic therapy for acute pelvic inflammatory disease: The 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines

Clinical Infectious Diseases

Volumn 44, Issue SUPPL. 3, 2007, Pages

  Walker, Cheryl K ^a   Wiesenfeld, Harold C ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Allegheny County Health Department   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; FLUCONAZOLE; GENTAMICIN; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN; PROBENECID; SECNIDAZOLE; SULTAMICILLIN; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDES FRAGILIS; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; COMORBIDITY; DRUG COST; DRUG USE; EVALUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MEDICAL LITERATURE; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PELVIC INFLAMMATORY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; PUBLICATION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

ADULT; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MIDDLE AGED; PELVIC INFLAMMATORY DISEASE; PRACTICE GUIDELINES; SEXUALLY TRANSMITTED DISEASES; TREATMENT OUTCOME;

EID: 33947357045     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511424     Document Type: Article

References (67)

1. Sutton MY, Sternberg M, Saidi A, St. Louis ME, Markowitz LE. Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985-2001. Sex Transm Dis 2005; 32:778-84.
2. Velebil P, Wingo PA, Xia Z, Wilcox LS, Peterson HB. Rate of hospitalization for gynecologic disorders among reproductive-age women in the United States. Obstet Gynecol 1995; 86:764-9.
3. Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing but still substantial. Obstet Gynecol 2000; 95:397-402.
4. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002; 51(RR-6):1-78.
5. 2005 Cardinal distribution. Dublin, OH: Cardinal Health, 2005.
6. Sweet RL. Pelvic inflammatory disease and infertility in women. Infect Dis Clin North Am 1987; 1:199-215.
7. Wasserheit JN, Bell TA, Kiviat NB, et al. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann Intern Med 1986; 104:187-93.
8. Heinonen PK, Teisala K, Punnonen R, et al. Anatomic sites of upper genital tract infection. Obstet Gynecol 1985; 66:384-90.
9. Paavonen J, Teisala K, Heinonen PK, et al. Microbiological and histopathological findings in acute pelvic inflammatory disease. Br J Obstet Gynaecol 1987; 94:454-60.
10. Brunham RC, Binns B, Guijon F, et al. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis 1988; 158:510-7.
11. Soper DE, Brockwell NJ, Dalton HP, Johnson D. Observations concerning the microbial etiology of acute salpingitis. Am J Obstet Gynecol 1994; 170:1008-14.
12. Hillier SL, Kiviat NB, Hawes SE, et al. Role of bacterial vaginosis-associated microorganisms in endometritis. Am J Obstet Gynecol 1996; 175:435-41.
13. Sweet RL, Draper DL, Schachter J, James J, Hadley WK, Brooks GF. Microbiology and pathogenesis of acute salpingitis as determined by laparoscopy: what is the appropriate site to sample? Am J Obstet Gynecol 1980; 138(7 Pt 2):985-9.
14. Haggerty CL, Hillier SL, Bass DC, et al. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis 2004; 39:990-5.
15. Haggerty CL, Ness RB, Amortegui A, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol 2003; 188:141-8.
16. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol 2002; 186:929-37.
17. Aldridge KE, Ashcraft D, Cambre K, et al. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001; 45:1238-43.
18. Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004; 191:1124-9.
19. Hemsell DL, Heard MC, Hemsell PG, Nobles BJ. Sulbactam/ampicillin versus cefoxitin for uncomplicated and complicated acute pelvic inflammatory disease. Drugs 1988; 35(Suppl 7):39-52.
20. Sweet RL, Landers DV, Schachter J, Crombleholme WR. Sulbactam/ ampicillin in the treatment of acute pelvic inflammatory disease. Suppl Int J Gynaecol Obstet 1989; 2:13-9.
21. Hemsell DL, Bawdon RE, Hemsell PG, Nobles BJ, Heard MC. Single-agent therapy for acute pelvic inflammatory disease: sulbactam/ampicillin versus cefoxitin. J Int Med Res 1990; 18(Suppl 4):85D-9D.
22. McGregor JA, Crombleholme WR, Newton E, Sweet RL, Tuomala R, Gibbs RS. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994; 83:998-1004.
23. Owens RCJ, Rice L. Hospital-based strategies for combating resistance. Clin Infect Dis 2006; 42(Suppl 4):S173-81.
24. Walker CK, Kahn JG, Washington AE, Peterson HB, Sweet RL. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. J Infect Dis 1993; 168:969-78.
25. Peipert JF, Sweet RL, Walker CK, et al. Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease. Infect Dis Obstet Gynecol 1999; 7:138-44.
26. Stein GE, Goldstein EJC. Fluoroquinolones and anaerobes. Clin Infect Dis 2006; 42:1598-607.
27. Gonococcal Isolate Surveillance Project (GISP). Sexually transmitted disease surveillance 2004 supplement. GISP annual report 2004. Available at: http://www.cdc.gov/std/GISP2004/GISP2004.pdf. Accessed 26 January 2007.
28. Iverson CJ, Wang SA, Lee MV, et al. Fluoroquinolone resistance among Neisseria gonorrhoeae isolates in Hawaii, 1990-2000: role of foreign importation and increasing endemic spread. Sex Transm Dis 2004; 31: 702-8.
29. Newman LM, Wang SA, Ohye RG, et al. The epidemiology of fluoroquinolone-resistant Neisseria gonorrhoeae in Hawaii, 2001. Clin Infect Dis 2004; 38:649-54.
30. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55:10-21.
31. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003; 31:45-54.
32. Sweet RL, Schachter J, Landers DV, Ohm-Smith M, Robbie MO. Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and cefoxitin plus doxycycline. Am J Obstet Gynecol 1988; 158(3 Pt 2):736-41.
33. Landers DV, Wolner-Hanssen P, Paavonen J, et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. Am J Obstet Gynecol 1991; 164:849-58.
34. Hillier SL, Kiviat NB, Hawes SE, et al. Role of bacterial vaginosis-associated microorganisms in endometritis. Am J Obstet Gynecol 1996; 175:435-41.
35. Matsuda S, Oh K, Hirayama H. Pharacokinetic and clinical evaluation of levofloxacin in obstetrical and gynecological field. Jpn J Antibiot 1992; 45:285-92.
36. Malhotra M, Sharma JB, Batra S, Arora R, Sharma S. Ciprofloxacin- tinidazole combination, fluconazole-azithromicin-secnidizole-kit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian J Med Sci 2003; 57:549-55.
37. Hong S, Kin C, Qianhong Y, et al. Pelvic inflammatory disease in the People's Republic of China: aetiology and management. Int J STD AIDS 2002; 13:568-72.
38. Dunbar-Jacob J, Sereika SM, Foley SM, Bass DC, Ness RB. Adherence to oral therapies in pelvic inflammatory disease. J Womens Health (Larchmt) 2004; 13:285-91.
39. Nathwani D, Zambrowski JJ, AdHOC Workshop. Advisory group on home-based and outpatient Care (AdHOC): an international consensus statement on non-inpatient parenteral therapy. Clin Microbiol Infect 2000; 6:464-76.
40. Leggett JE. Ambulatory use of parenteral antibacterials: contemporary perspectives. Drugs 2000; 59(Suppl 3):1-8.
41. Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA, eds. The Sanford guide to antimicrobial therapy 2005. Hyde Park, VT: Antimicrobial Therapy, 2005.
42. Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005.
43. Yip L, Sweeny PJ, Bock BF. Acute suppurative salpingitis with concomitant intrauterine pregnancy. Am J Emerg Med 1993; 11:476-9.
44. Blanchard AC, Pastorek JG 2nd, Weeks T. Pelvic inflammatory disease during pregnancy. South Med J 1987; 80:1363-5.
45. Lardaro HH. Spontaneous rupture of tubo-ovarian abscess within the free peritoneal cavity. JAMA 1954; 156:699.
46. Franklin EW, Heuron JD, Thompson JD. Management of pelvic abscess. Clin Obstet Gynecol 1973; 16:66.
47. Collins CG, Nex FC, Cerrha HT. Ruptured tubo-ovarian abscess. Am J Obstet Gynecol 1956; 72:820.
48. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100:456-63.
49. Sweet RL, Schachter J, Robbie MO. Failure of beta-lactam antibiotics to eradicate Chlamydia trachomatis in the endometrium despite apparent clinical cure of acute salpingitis. JAMA 1983; 250:2641-5.
50. Hemsell DL, Ledger WJ, Martens M, Monif GR, Osborne NG, Thomason JL. Concerns regarding the Centers for Disease Control's published guidelines for pelvic inflammatory disease. Clin Infect Dis 2001; 32:103-7.
51. Jamieson DJ, Duerr A, Macasaet MA, et al. Risk factors for a complicated clinical course among women hospitalized with pelvic inflammatory disease. Infect Dis Obstet Gynecol 2000; 8:88-93.
52. Halperin R, Levinson O, Yaron M, et al. Tubo-ovarian abscesses in older women: is the woman's age a risk factor for failed response to conservative treatment? Gynecol Obstet Invest 2003; 55:211-5.
53. Protopapas AG, Diakomanolis ES, Milingos SD, et al. Tubo-ovarian abscesses in postmenopausal women: gynecological malignancy until proven otherwise? Eur J Obstet Gynecol Reprod Biol 2004; 114:203-9.
54. Korn AP, Landers DV, Green JR, Sweet RL. Pelvic inflammatory disease in human immunodeficiency virus-infected women. Obstet Gynecol 1993; 82:765-8.
55. Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000; 95:525-34.
56. Cohen CR, Sinei S, Reilly M, et al. Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. J Infect Dis 1998; 178:1352-8.
57. Bukusi EA, Cohen CR, Stevens CE, et al. Effects of human immunodeficiency virus 1 infection on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy. Am J Obstet Gynecol 1999; 181:1374-81.
58. Swenson CE, Schachter J. Infertility as a consequence of chlamydial infection of the upper genital tract in female mice. Sex Transm Dis 1984; 11:64-7.
59. Hillis SD, Joesoef R, Marchbanks PA, Wasserheit JN, Cates W Jr, Westrom L. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168:1503-9.
60. Viberg L. Acute inflammatory conditions of the uterine adnexa: clinical, radiological and isotopic investigations of non-gonococcal adnexitis. Acta Obstet Gynecol Scand 1964; 43(Suppl 4):1-86.
61. Wiesenfeld HC, Sweet RL, Ness RB, Krohn MA, Amortegui AJ, Hillier SL. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis 2005; 32:400-5.
62. World Health Organization Task Force on the Prevention and Management of Infertility. Tubal infertility: serologic relationship to post chlamydial and gonococcal infection. Sex Transm Dis 1995; 22:71-7.
63. Korn AP, Hessol NA, Padian NS, et al. Risk factors for plasma cell endometritis among women with cervical Neisseria gonorrhoeae, cervical Chlamydia trachomatis, or bacterial vaginosis. Am J Obstet Gynecol 1998; 178:987-90.
64. Eschenbach DA, Holmes KK. Acute pelvic inflammatory disease: current concepts of pathogenesis, etiology, and management. Clin Obstet Gynecol 1975; 18:35.
65. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339:785-8.
66. Soderberg G, Lindgren S. Influence of an intrauterine device on the course of an acute salpingitis. Contraception 1981; 24:137-43.
67. Altunyurt S, Demir N, Posaci C. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 2003; 107:81-4.